In his first public appearance as Incyte’s CEO, Bill Meury outlined his priorities for the company, including taking a “fresh look” at the business across R&D, operating expenses and capital allocation. More: Incyte's new CEO pledges 'fresh look' at business,
read moreAs Eli Lilly rolls ahead with a $27 billion investment to prop up four new manufacturing facilities in the U.S, the company is moving to offload another plant with a checkered past. More: Lilly confirms plan to sell NJ plant
read more
US$30.9 million strategic equity deal strengthens oncology platform More: US.9 million strategic equity deal strengthens Everest’s oncology platform Source: News
read more
MB310 study investigates safety and efficacy of precision microbiome therapy More: Microbiotica completes recruitment for phase 1b ulcerative colitis trial Source: News
read moreThe changes come after a public advisory committee meeting in May, which reviewed data from two large observational studies showing serious risks for patients who use opioids over a long time. More: FDA requires label changes to all opioid pain
read moreRegeneron is having difficulties again with its manufacturing partner Novo Nordisk, reporting that it expects two FDA decisions due this month for its eye disease drug Eylea will be delayed, while another application for its cancer bispecific has received a
read more© 1994 - 2026 B.M. Pharmaceuticals